What Albunorm Treats: Main Uses and Benefits

Albunorm is commonly used across clinical settings that involve acute or unstable symptom patterns to provide supportive benefits for critical situations. It is relevant for symptoms related to systemic imbalance, addressing symptoms that create noticeable physiological strain related to circulation and fluid imbalances in situations where patients experience severe protein loss. The solution is applied when appropriate for the restoration of circulating blood volume.

---

Support for Critical Physiological States

This medicine is commonly used to help with addressing symptoms of critical volume loss and shock, such as dangerously low blood pressure. It is often applied in acute scenarios, including following severe trauma, extensive burns, or during septic shock. Albunorm is also considered relevant in conditions presenting with systemic or localized discomfort, such as severe generalized swelling (anasarca) or significant abdominal fluid accumulation (ascites).

Quick Fact: Relief for Fluid Imbalance The therapy supports the body during episodes of heightened discomfort by helping to address the low protein levels associated with fluid loss.

Albunorm is relevant support for specific acute complications of conditions marked by increased physiological stress, such as advanced liver cirrhosis. It may assist with maintaining functional stability in clinical settings that involve acute or unstable symptom patterns, such as following large-volume paracentesis or severe infections. Its use plays a role in managing the severe plasma protein deficits associated with extensive burn injuries.

“This therapy is commonly used to help with symptoms that create noticeable physiological strain during difficult episodes by easing the distress associated with acute volume loss or severe fluid imbalance.”

Official Eligibility and Restrictions

Albunorm (Human Albumin) is strictly contraindicated for use in individuals with a known hypersensitivity or allergy to human albumin preparations or any of the product's excipients.

Its use requires special caution in patients with conditions where an increase in circulating blood volume (hypervolaemia) or the dilution of blood components (haemodilution) could pose a significant risk. These conditions include:

• Decompensated cardiac insufficiency (severe heart problems)
• Hypertension (high blood pressure)
• Oesophageal varices (dilated veins in the esophagus)
• Pulmonary oedema (fluid in the lungs)
• Hemorrhagic diathesis (bleeding disorders)
• Severe anaemia (severely low red blood cell count)
• Renal and post-renal anuria (no urine output/kidney failure)

Additionally, caution is advised when administering Albunorm to patients with severe traumatic brain injury, as some studies have shown an association with higher mortality rates in this specific population. The product's safety for use during pregnancy has not been established in controlled trials, and it should only be administered if clearly necessary.

Interactions with other medicines and products

Official regulatory documentation states that no specific systemic interactions of human albumin, the active substance in Albunorm, with other medicinal products are currently known. The key interaction constraints documented in official labeling are purely procedural and relate to the physical administration and handling of the solution, primarily to prevent incompatibility or adverse patient effects during infusion.

---

Documented Interaction Constraints

The interaction profile of Albunorm is structured by restrictions on mixing and dilution, which are mandatory conditions for safe use:

• Infusion Mixture Restriction: The Albunorm solution must not be mixed in the same infusion container or line with other medicinal products. This constraint extends to whole blood or packed red cells, preventing potential physical incompatibility between the substances prior to administration.

• Dilution Constraint: The solution must not be diluted with water for injections. This is a critical instruction to avoid the risk of haemolysis (destruction of red blood cells) in the recipient.

These constraints establish that the risk of interaction is based on physicochemical incompatibility during co-administration rather than altered pharmacokinetics, enzyme inhibition, or induction. The regulatory guidance is definitive: follow these procedural constraints to ensure proper product integrity and patient safety.

Regulating Plasma Colloid Osmotic Pressure

Albunorm (human albumin) acts as the primary determinant of plasma colloid osmotic pressure within the vascular space. This mechanistic domain involves the high-molecular-weight protein mediating a net shift of water from the interstitial space into the plasma compartment via osmosis. The resulting physiological consequence is a predictable increase in circulating blood volume due to the enhanced fluid mobilization across the vascular barrier.

Mediating Molecular Transport and Binding

Albunorm functions as a non-specific carrier protein, which is a key mechanistic domain for modulating physiological pathways. Albumin's multiple binding sites allow it to non-covalently bind and transport a wide range of endogenous compounds, such as fatty acids, bilirubin, and hormones, as well as exogenous molecules. This engagement with circulating substances binds and modulates the concentration of various mediators, thereby influencing systemic molecular distribution.

Influencing Vascular and Oxidation Processes

Albunorm exerts effects relevant in systems involving oxidative stress and vascular integrity. This domain includes engaging mechanisms that modulate local factors influencing vascular endothelial health. The molecule acts as an antioxidant by scavenging free radicals, a pathway effect that impacts processes related to capillary membrane function and overall vascular environment dynamics.

How Albunorm is Used: Administration Guidelines

Albunorm is a medication for professional use, and its administration follows established clinical principles, focusing on procedural constraints and dose calculation. The solution is intended for administration via intravenous (IV) infusion. It is typically available in two concentrations, such as 50 g/L (5%) or 200 g/L (20%), to allow for varying physiological requirements.

---

Administration Protocol

The dosage and infusion rate for Albunorm are individually adjusted and depend primarily on the patient's measured circulating volume adequacy and fluid loss, rather than solely on the level of albumin in the blood. The maximum daily dose should generally not exceed 2 grams per kilogram of body weight. For acute volume loss, the starting dose in adults is often 25 grams, with subsequent doses based on the patient’s hemodynamic response within 15 to 30 minutes.

Preparation and Constraints

Procedurally, the solution must be administered immediately after the container is opened. If large volumes are required, the product should be warmed to room or body temperature prior to use. Albunorm may be administered directly or diluted using only specified isotonic solutions, such as 0.9% sodium chloride. A critical instruction is that the solution must not be diluted with water for injections, as this poses a risk of hemolysis. For pediatric patients with hypovolemia, the dose is calculated based on body weight, typically in the range of 0.5 to 1 gram per kilogram.

Research Evidence / Overview of Studies for Albunorm

Evidence for Use in Acute Circulatory Support and Shock

Research exploring the application of Human Albumin in patients requiring acute circulatory support, such as those with severe blood volume loss (hypovolemia) or advanced infections like septic shock, has primarily relied on large-scale Randomized Controlled Trials (RCTs) and comprehensive Meta-Analyses. Studies examined critically ill adults admitted to the Intensive Care Unit (ICU).

Research monitored key clinical outcomes, including patient survival (all-cause mortality) and the incidence of new Acute Kidney Injury (AKI). In the broad population of critically ill patients studied, some trials reported measurements where the use of Human Albumin was observed not to correspond with a reduction in overall all-cause mortality when compared to alternative intravenous volume replacement fluids.

However, specific studies focusing only on certain patient subsets, such as those diagnosed with septic shock, described patterns that differed from the overall general population findings. Such findings are typically considered limited and require confirmation by dedicated, planned prospective trials. The available evidence presents mixed findings related to survival outcomes.

Evidence for Use in Advanced Liver Disease Complications

The research exploring Human Albumin in complications of advanced liver disease, such as liver cirrhosis, includes numerous RCTs consolidated by Systematic Reviews. These studies explored the management of severe fluid accumulation in the abdomen (ascites) and severe bacterial infections like Spontaneous Bacterial Peritonitis (SBP). The populations examined were typically adults with established cirrhosis who were undergoing procedures like Large-Volume Paracentesis (LVP).

Studies monitored outcomes related to physiological strain, specifically focusing on the occurrence of circulatory instability, referred to as Paracentesis-Induced Circulatory Dysfunction (PICD). Research reports patterns related to the occurrence of PICD following the application of Human Albumin during LVP. Research also explored the application of Human Albumin in patients with SBP, monitoring the incidence of kidney dysfunction and other systemic imbalances.

While research reports patterns related to reduced acute complications following LVP, the overall mortality data, when pooled with all alternative treatments, may be variable. Research is ongoing to examine the optimal dosage schedule and administration practices for these conditions.

Long-Term Studies and Follow-up Durations

The majority of the defining research for Human Albumin in acute settings involves observation periods that are short-term (28 days) or intermediate-term (90 days) for key endpoints like mortality. While these intervals provide insight into the acute management, there is limited information for long-term outcomes or the durability of observed physiological patterns. Research is ongoing to better understand any extended effects or patterns of response over longer defined time intervals.

What Remains Uncertain About the Research

Research consistently highlights several areas of uncertainty and specific limitations within the current evidence landscape. The overall evidence quality varies across studies, and findings were mixed when considering broad populations of critically ill patients. A major gap is the lack of robust evidence showing a clear difference in survival outcomes when compared with alternative intravenous fluids in the general critical care population. Furthermore, certain findings that suggest specific patterns in patient subgroups were based on preliminary analyses, meaning these data are still emerging and require confirmation through dedicated prospective trials.

Key Studies & References

1. Albumin versus other fluid-resuscitation regimens for critically ill patients (Cochrane Review)

Common questions about Albunorm (FAQ)

Q: What is Albunorm and what is it used for?

Albunorm is an infusion solution that contains human albumin, which is a type of protein naturally found in your blood plasma. Albumin plays a crucial role in regulating blood volume and maintaining the correct pressure within blood vessels, known as oncotic pressure.

Albunorm is used to restore and maintain circulating blood volume when the loss of volume has occurred, and the use of a colloid (like albumin) is appropriate. This can happen in conditions such as significant blood loss, burns, or other conditions where there is a deficiency of protein or circulating fluid.

---

Q: How is Albunorm administered?

Albunorm is administered by a healthcare professional as an intravenous infusion (into a vein). The rate and volume of the infusion will depend on your specific condition, your body weight, and how much fluid you have lost or need to replace.

It is typically given in a hospital or clinical setting under close medical supervision to monitor your response and vital signs.

---

Q: What are the common side effects of Albunorm?

Like all medicines, Albunorm can cause side effects, although not everyone gets them. Mild and transient reactions may occur and usually disappear quickly when the infusion rate is slowed down or stopped. These are reported as uncommon (may affect up to 1 in 100 people).

Commonly reported side effects include:

• Flushing (redness of the face)
• Urticaria (hives or rash)
• Fever
• Nausea

If you experience a severe reaction, such as swelling of the face, tongue, or throat, difficulty breathing, or a drop in blood pressure, you should inform your doctor or nurse immediately, as these may indicate a severe allergic reaction that requires immediate attention.

---

Q: Is there anyone who should not receive Albunorm?

Yes. Albunorm should not be used if you are allergic (hypersensitive) to human albumin preparations or any of the other ingredients of Albunorm.

It should also be used with caution, and your doctor must be informed, if you have conditions where increased blood volume and its consequences could be a risk, such as:

• Decompensated heart failure (severe heart problems)
• Severe high blood pressure
• Oesophageal varices (enlarged veins in the food pipe)
• Lung oedema (fluid in the lungs)
• Kidney problems (anuria) and other conditions where fluid overload is a risk.

Your doctor will assess whether Albunorm is safe for you based on your medical history.

---

Q: What precautions are taken regarding the safety of Albunorm related to viruses and infections?

Albunorm is made from human plasma (the liquid part of blood). When medicines are made from human blood or plasma, steps are taken to minimize the risk of transmitting infections.

These steps include:

1. Selection of donors: Screening blood donors for specific infections.
2. Testing of plasma pools: Testing the collected plasma for the presence of viruses.
3. Manufacturing process: Including steps to inactivate or remove viruses (e.g., heat treatment, called pasteurization).

Despite these measures, the possibility of transmitting infectious agents cannot be totally excluded when administering medicinal products made from human blood or plasma. Your doctor will weigh the risk against the benefit of using Albunorm.

How to Store and Dispose of Albunorm?

Albunorm (human albumin solution) requires strict adherence to regulatory instructions to maintain its stability and integrity.

---

Official Storage Requirements

Condition	Regulatory Requirement
Temperature	Store at a temperature not exceeding 25 C (77 F).
Handling	Do not freeze the solution.
Container/Light	Store in the original container to protect from light.
Stability	The solution must be used immediately once the container has been opened.
Safety	Keep this medicine out of the sight and reach of children.

---

Disposal of Unused Medicine

Any unused portion of the product remaining after infusion must be discarded. Official instructions forbid disposal via wastewater or household waste. Expired or unwanted Albunorm must be disposed of according to local requirements for pharmaceutical waste, often through a pharmacy or authorized collection point.